title: Ajmaline challenge for the diagnosis of Brugada syndrome: which protocol?
abstract: BACKGROUND
  Ajmaline challenge is commonly used for the diagnosis of Brugada syndrome. A slow infusion rate has been recommended in view of the proarrhythmic risk, but the diagnostic value of various infusion rates has not been investigated.
  
  
  OBJECTIVE
  To compare rapid and slow ajmaline infusion rates and to assess the proarrhythmic risk.
  
  
  METHODS
  The first part of this study prospectively compared rapid and slow infusion rates in terms of results and ventricular arrhythmias. Thirty-two patients (mean age 41±12 years; 26 men) received the two ajmaline challenges on different days. According to randomization, ajmaline (1 mg/kg) was infused at 1 mg/sec or over 10 minutes. The second part of the study retrospectively assessed the prevalence of ventricular arrhythmia during 386 challenges performed at a rapid infusion rate.
  
  
  RESULTS
  No differences were observed between rapid and slow tests. All patients diagnosed as positive or negative with one test obtained the same result with the other test. Ventricular premature beats were observed in five of 32 patients during the slow challenge and in four of 32 patients during the rapid challenge. No sustained ventricular arrhythmias were observed. Analysis of the 386 tests revealed four episodes of ventricular arrhythmia (two complex ventricular premature beats, one non-sustained ventricular tachycardia and one ventricular fibrillation).
  
  
  CONCLUSIONS
  Slow and rapid infusions of ajmaline have identical diagnostic performances on suspected Brugada electrocardiograms. Owing to the risk of severe proarrhythmia, a slow infusion rate, allowing early discontinuation, should be recommended.
authors.affiliation: Centre d'activité de rythmologie, Amiens-Picardie University Hospital, 80054 Amiens cedex 1, France.
authors.forename: Elise
authors.initials: E
authors.lastname: Arnalsteen-Dassonvalle
authors.forename: Jean-Sylvain
authors.initials: JS
authors.lastname: Hermida
authors.forename: Maciev
authors.initials: M
authors.lastname: Kubala
authors.forename: Isabelle
authors.initials: I
authors.lastname: Six
authors.forename: Serge
authors.initials: S
authors.lastname: Quenum
authors.forename: Laurent
authors.initials: L
authors.lastname: Leborgne
authors.forename: Geneviève
authors.initials: G
authors.lastname: Jarry
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000404:Ajmaline / Q000008:administration & dosage / Q000009:adverse effects; D053840:Brugada Syndrome / Q000175:diagnosis*; D018592:Cross-Over Studies; D004562:Electrocardiography; D005260:Female; D005602:France; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012189:Retrospective Studies; D017180:Tachycardia, Ventricular / Q000139:chemically induced; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000139:chemically induced; D018879:Ventricular Premature Complexes / Q000139:chemically induced; D055815:Young Adult
chemical_list: D000404:Ajmaline